---
document_datetime: 2025-01-17 16:21:23
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gavreto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: gavreto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.4966836
conversion_datetime: 2025-12-19 06:04:44.382922
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

| Application number   | Scope                                                     | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| T/0021               | Transfer of Marketing Authorisation                       | 21/06/2024                                  | 17/07/2024                                  | SmPC, Labelling and PL           |                                   |
| PSUSA/10961 /202309  | Periodic Safety Update EU Single assessment - pralsetinib | 11/04/2024                                  | n/a                                         |                                  | PRAC Recommendation - maintenance |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2

GAVRETO Procedural steps taken and scientific information after the authorisation Application number Scope Commission Decision Issued 2 / amended Product Information affected 3 Summary T/0021 Transfer of Marketing Authorisation 17/07/2024 SmPC, Labelling and PL PSUSA/10961 /202309 Periodic Safety Update EU Single assessment pralsetinib n/a PRAC Recommendation - maintenance Medicinal product no longer authorised

A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0012   | Update of sections 4.2, 4.4 and 4.5 of the SmPC in order to amend posology recommendations, warnings and drug-drug interaction information regarding the co-administration with CYP3A4 inhibitors, P-gp inhibitors and CYP3A4 inducers based on final results from the DDI study GP43162, listed as a category 3 study in the RMP, as well as results from the physiologically based pharmacokinetic (PBPK) analyses summarised in the PBPK Report 1120689. Study GP43162 is a phase 1, open-label, fixed-sequence study to evaluate the effect of a single dose of cyclosporine on the single dose pharmacokinetics of pralsetinib in healthy subjects. The package leaflet has been updated accordingly. The RMP version 1.8 is agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 22/02/2024   | 25/03/2024 no   | SmPC and PL longer   | Section 4.2 is updated with specific dose modifications when co-administered with CYP3A4 inhibitors and/or p-gp inhibitors. The recommended dose modifications for co- administration with CYP3A4 inducers have been deleted. Sections 4.4 and 4.5 are updated to describe in further details on the warnings that concomitant use with CYP3A4 and/or p-gp inhibitors and CYP3A4 inducers should be avoided. For more information, please refer to the Summary of Product Characteristics. authorised   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0017   | Update of sections 4.2 and 5.2 of the SmPC in order to include information regarding moderate and severe hepatic impairment based on final results from study GP43163 listed as a category 3 study in the RMP; this is a Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of pralsetinib in subjects with moderate or severe hepatic impairment compared to healthy subjects. The RMP version 1.8 is agreed. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to update the marketing authorisation renewal date in Annex I. Medicinal product                                                                                                                                                                                                         | 22/02/2024   | 25/03/2024      | SmPC and PL          | Following the results from a Phase I, open-label, single- dose study to evaluate the pharmacokinetics and safety of pralsetinib in subjects with moderate or severe hepatic impairment compared to healthy subjects, sections 4.2 and 5.2 of the SmPC have been updated in order to mention that no dose adjustment is necessary for patients wild mild, moderate or strong hepatic impairment. For more information, please refer to the Summary of Product Characteristics.                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0016/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits 30/11/2023 Medicinal product no |

<div style=\"page-break-after: always\"></div>

|                     | increase compared to the originally approved batch size B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |               |             | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10961 /202303 | Periodic Safety Update EU Single assessment - pralsetinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/09/2023 | n/a           |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0014              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/07/2023 | 15/09/2023 no | longer      | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for GAVRETO, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.                                                                                                                                                                |
| II/0013             | Update of sections 4.4, 4.6 and 5.3 of the SmPC in order to update information on fertility based on final results from study 00571044 (21-0310); this is a 9- week fertility and toxicokinetic study of pralsetinib administered via oral gavage in male Sprague Dawley rats. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce a minor change to the PI and update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance Medicinal product | 20/07/2023 | 15/09/2023    | SmPC and PL | SmPC new text It was specified in sections 4.4 and 4.6 of the SmPC that effective contraception, which must be used by males with females partners of childbearing potential, includes a barrier method. Section 5.3 of the SmPC was updated to reflect the results of a fertility and early embryonic development study in which male rats administered pralsetinib were mated with untreated female rats and the fact that both intrauterine survival of the embryos and male reproductive performance were unaffected by pralsetinib administration to males at the 20 mg/kg dose level. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |               |                   | Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10961 /202209 | Periodic Safety Update EU Single assessment - pralsetinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/04/2023 | 07/07/2023    | SmPC and PL       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10961/202209.                                                                                                                                                                                                                                                                                                                                     |
| II/0010             | Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to update PK/PD, efficacy and safety information in the treatment of adult patients with RET fusion-positive advanced NSCLC based on final results (NSCLC indication) from study ARROW/BO42863 (also known as BLU-667-1101), a Phase 1/2 Study of the Highly-selective RET Inhibitor in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumours listed as a specific obligation in the Annex II. The specific obligation is considered fulfilled and deleted from the Annex II. The RMP version 1.5 is agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance product | 22/06/2023 | 15/09/2023 no | SmPC and Annex II | SmPC new text Based on the final result of a Phase 1/2 Study of the Highly-selective RET Inhibitor, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumours, safety, efficacy and PK data have been updated in sections 4.8, 5.1 and 5.2 of the SmPC. The final results of this study are overall consistent with previous data. For more information, please refer to the Summary of Product Characteristics. longer authorised |
| IB/0011/G           | data This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.3.a - Change in the manufacturing process of Medicinal                                                                                                                                                                                                                                                                                                                                                                                                      | 10/01/2023 | n/a           |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | the finished or intermediate product - Minor change in the manufacturing process B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or product   |            | no         | longer   | authorised                        |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| PSUSA/10961 /202203 | manufacturer of a novel excipient Periodic Safety Update EU Single assessment - pralsetinib Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 29/09/2022 | n/a        |          | PRAC Recommendation - maintenance |
| R/0006              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21/07/2022 | 13/09/2022 |          |                                   |
| IB/0008             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/06/2022 | 13/09/2022 | SmPC     |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0004/G   | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation   | 22/03/2022   | 13/09/2022   | SmPC and PL     | PI was update to relfect extension of the shelf life of the finished product from 24 to 30 months for Pralseltinib 100 mg capsules. authorised   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                          | 28/02/2022   | n/a no       | longer          |                                                                                                                                                  |
| IB/0003/G   | This was an application for a group of variations. B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation product                                                                                                                                                                                                                                                                                                                                             | 09/02/2022   | n/a          |                 |                                                                                                                                                  |
| IAIN/0001/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing Medicinal                                                                                                                                                                                                                    | 10/12/2021   | 13/09/2022   | Annex II and PL |                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->